Biopharma Pulse - 5/2 - 5/6 Week in Review
- BPIQ
- May 6, 2022
- 2 min read
As we enter May, we review moves from smid-cap biopharma companies during this past week as well as in the month of April. See Table 1 for weekly moves and moves YTD for companies and categories on BPIQ.com compared to XBI.
Table 1. BPIQ company weekly/monthly moves and YTD moves
Category | Weekly Move (5/2 - 5/6) | April Move | YTD Move |
|---|---|---|---|
All BPIQ Companies | -4.48% | -21.74% | -44.42% |
CAR-T Companies | -2.11% | -23.44% | -49.48% |
Gene Editing Companies | -0.24% | -25.15% | -48.55% |
XBI | -5.01% | -17.86% | -37.36% |
See the biggest moves from last week below:
Don't miss upcoming catalysts.. Get our weekly Catalyst Watchlist Free!
*We never send you spam - unsubscribe anytime
Highlights for the week of 5/2 - 5/6
Biggest positive move
$EVFM +677.8% Evofem Biosciences Announces 1-for-15 Reverse Stock Split
Biggest negative move
$CNTB -69.5% Connect Biopharma Announces Week 12 Top-Line Results from Phase 2 CBP-307 Trial in Patients with Moderate-to-Severe Ulcerative Colitis
Highlights for the month of April 2022
Biggest positive move
$CMPI +225.4% Regeneron to Acquire Checkmate Pharmaceuticals and Its Investigational Immune Activator for Potential Use in Multiple Tumor Types
Biggest negative move
$KLDO -96.97%
Additional big moves
$SESN +30.0% Sesen Bio Provides Strategic Update.
$ICPT +21.0% INTERCEPT ANNOUNCES ADVANZ PHARMA TO ACQUIRE OCALIVA IN PBC IN MARKETS OUTSIDE THE U.S. FOR UP TO $450MM, INCLUDING $405MM UPFRONT AND AN ADDITIONAL $45MM IN CONTINGENT PAYMENTS
$KALA +17.0% Kala Pharmaceuticals to Present Clinical Data for KPI-012, its Mesenchymal Stem Cell Secretome Product, for the Treatment of PCED at the 2022 ARVO Annual Meeting.
$HGEN +14.4% Humanigen Reports First Quarter 2022 Financial Results
$JNCE +13.0% Jounce upgraded to Strong Buy at Raymond James after pipeline updates
$AXGN +10.8% Axogen, Inc. Announces Positive Topline Results from Phase 3 RECON(SM) Study for Avance® Nerve Graft
$ANIX +10.6% Anixa Biosciences (ANIX): Partner Cleveland Clinic to present Breast Cancer Vaccine Trial at ASCO.
$GRTX +10.1% Galera Announces Topline Results from Phase 2a AESOP Trial of Avasopasem for Chemoradiotherapy-Induced Esophagitis.
$VERU -12.4% FDA Has Granted Veru a Pre-Emergency Use Authorization (EUA) Meeting Date for Positive Sabizabulin Phase 3 COVID-19 Study.
$SANA -15.5% Sana Biotechnology to Present at the BofA Securities 2022 Healthcare Conference
$EVFM -15.5% Evofem Presents Data Detailing Fewer Urinary Tract Infections in Women Using Phexxi in the Phase 3 AMPOWER Clinical Trial.
$HCM -19.0% HUTCHMED Receives Complete Response Letter from the U.S. FDA for Surufatinib for the Treatment of Advanced Neuroendocrine Tumors.
$TARS -23.5% Tarsus Announces Positive Topline Data from Saturn-2 Phase 3, the Second Pivotal Trial of TP-03 for the Treatment of Demodex Blepharitis, and Expects to File a New Drug Application This Year.
$KZR -24.5% Kezar Announces Topline Results from PRESIDIO Trial of Zetomipzomib for the Treatment of Dermatomyositis and Polymyositis
$IPSC -28.7% Century Therapeutics to Present at Upcoming Investor Conferences
$ENDP -29% ENDO REPORTS FIRST-QUARTER 2022 FINANCIAL RESULTS
$CLVS -50.5% Clovis Oncology Announces First Quarter 2022 Operating Results and Provides Update on Clinical Development Programs
$SPRO -63.7% Spero Therapeutics Announces New Strategic Direction Focusing on Advancing Promising Clinical-Stage Pipeline.
Highlights for next week
To see next week's Big Movers HERE, subscribe. Learn more here.
Watch for quarterly reports from commercial companies
$KOD Phase 2/3 update
See our Big Movers post to learn about upcoming Movers throughout May and PDUFAs, after subscribing. Learn more here.
Comments